Volume | 192,988 |
|
|||||
News | - | ||||||
Day High | 13.44 | Low High |
|||||
Day Low | 12.15 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Kyverna Therapeutics Inc | KYTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
12.32 | 12.15 | 13.44 | 13.00 | 12.43 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,607 | 192,988 | $ 12.74 | $ 2,458,601 | - | 12.15 - 35.01 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:04 | formt | 1,208 | $ 13.00 | USD |
Kyverna Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
530.69M | 40.82M | - | 0 | -60.37M | -1.48 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Kyverna Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KYTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 15.32 | 17.06 | 12.15 | 13.96 | 271,393 | -2.32 | -15.14% |
1 Month | 15.75 | 17.55 | 12.15 | 14.86 | 401,046 | -2.75 | -17.46% |
3 Months | 27.50 | 30.60 | 12.15 | 20.79 | 391,572 | -14.50 | -52.73% |
6 Months | 34.25 | 35.01 | 12.15 | 22.93 | 418,993 | -21.25 | -62.04% |
1 Year | 34.25 | 35.01 | 12.15 | 22.93 | 418,993 | -21.25 | -62.04% |
3 Years | 34.25 | 35.01 | 12.15 | 22.93 | 418,993 | -21.25 | -62.04% |
5 Years | 34.25 | 35.01 | 12.15 | 22.93 | 418,993 | -21.25 | -62.04% |
Kyverna Therapeutics Description
Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna¿s pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases. |